Approaches to recording drug allergies in electronic health records: qualitative study. by Fernando, Bernard et al.
FERNANDO, B., MORRISON, Z., KALRA, D., CRESSWELL, K. and SHEIKH, A. 2014. Approaches to recording drug 
allergies in electronic health records: qualitative study. PLoS ONE [online], 9(4), article ID e93047. Available from: 
https://doi.org/10.1371/journal.pone.0093047.  
Approaches to recording drug allergies in 
electronic health records: qualitative study. 
FERNANDO, B., MORRISON, Z., KALRA, D., CRESSWELL, K. and     
SHEIKH, A. 
2014 
This document was downloaded from 
https://openair.rgu.ac.uk 
 
Approaches to Recording Drug Allergies in Electronic
Health Records: Qualitative Study
Bernard Fernando1, Zoe Morrison1, Dipak Kalra2, Kathrin Cresswell3, Aziz Sheikh1,4,5*
1 eHealth Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, United Kingdom, 2Centre for Health Informatics and
Multiprofessional Education, University College London, London, United Kingdom, 3 The School of Health in Social Science, The University of Edinburgh, Edinburgh,
United Kingdom, 4Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, United Kingdom, 5Harvard
Medical School & Harkness Fellow in Health Care Policy and Practice, Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital/Harvard
Medical School, Boston, Massachusetts, United States of America
Abstract
Background: Drug allergy represent an important subset of adverse drug reactions that is worthy of attention because
many of these reactions are potentially preventable with use of computerised decision support systems. This is however
dependent on the accurate and comprehensive recording of these reactions in the electronic health record. The objectives
of this study were to understand approaches to the recording of drug allergies in electronic health record systems.
Materials and Methods: We undertook a case study comprising of 21 in-depth interviews with a purposefully selected
group of primary and secondary care clinicians, academics, and members of the informatics and drug regulatory
communities, observations in four General Practices and an expert group discussion with 15 participants from the Allergy
and Respiratory Expert Resource Group of the Royal College of General Practitioners.
Results: There was widespread acceptance among healthcare professionals of the need for accurate recording of drug
allergies and adverse drug reactions. Most drug reactions were however likely to go unreported to and/or unrecognised by
healthcare professionals and, even when recognised and reported, not all reactions were accurately recorded. The process
of recording these reactions was not standardised.
Conclusions: There is considerable variation in the way drug allergies are recorded in electronic health records. This limits
the potential of computerised decision support systems to help alert clinicians to the risk of further reactions. Inaccurate
recording of information may in some instances introduce new problems as patients are denied treatments that they are
erroneously believed to be allergic to.
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Introduction
Adverse drug reactions are very common [1]; they now, for
example, account for an estimated 6.5% of hospital admissions in
the United Kingdom (UK) [2]. The risk of one or more adverse
drug reactions (i.e. responses to medical products that are noxious
and unintended) occurring as a result of drugs initiated at the time
of admission to the hospital or continued in hospital has been
estimated at 14.7%, of which just over half are judged to be
possibly or definitely avoidable [3]. An estimated 0.7–2.3% of
deaths following adult emergency admissions with adverse events
(i.e. undesirable events experienced by patients whilst taking
medicines) are attributed to treatment in primary care [4].
Drug allergies represent an important subset of adverse drug
reactions (see Table 1). These are of particular interest because
these can result in life-threatening reactions and are often
preventable, particularly in the context of managing those with
known drug allergies. Clinical computerised decision support
systems (CDSS) in prescribing modules are widely seen as having
considerable potential to reduce the risk of allergic reactions to
drugs by drawing on information held in electronic health records
(EHRs) to generate tailored alerts in real-time [5–7]. This is
because CDSS have the potential to reduce prescribing errors and
thus repeat exposure to drugs (or similar classes of drugs) for which
a drug allergy is already recorded in the system. CDSS tools are
now widely used in primary care in the UK, and are increasingly
being made available in hospitals both in the UK and
internationally [8,9]. Irrespective of the setting, these CDSS are
crucially dependant on the availability of accurate clinical
information in coded format so as to enable the underlying
algorithms to successfully operate [10].
Understanding how drug allergies are currently recorded is
therefore important as such information can inform deliberations
on how to realise the potential offered by the prescribing decision
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support systems that are now increasingly embedded in EHRs.
This study aimed to address an important gap in the documented
knowledge of current practices of recording adverse drug reactions
and in particular drug allergies in EHRs. We were commissioned
by England’s Department of Health to undertake an investigation
into current recording practices of drug allergy and other adverse
drug reactions in order to inform deliberations on how to enhance
patient safety.
Materials and Methods
Design
CDSS used in prescribing modules are an important example of
what are sometimes known as eHealth interventions [11]. They
are now often designed and evaluated as sociotechnical interven-
tions [12] rather than purely technological innovations as was the
case in the recent past. Due consideration to human and
organisational factor considerations is crucial to the successful
implementation and adoption of these systems [13,14]. We sought
to investigate recording of adverse reactions and the interplay
between social and technical aspects of this process by exploring
behaviours in context using a qualitative case study approach [15].
This approach allows an in-depth multifaceted exploration of
complex issues in their real-life settings. The process of recording
allergic drug reactions electronically, and the value derived from
recording, was conceptualised as a case and investigated using a
combination of interviews, documentary analysis and observa-
tions.
Ethics and governance
We received ethical approval for this work from the National
Research Ethics Service – Brighton West Ethics Committee
(MREC Ref: 10/H1111/25). The research team obtained site-
specific permissions from local Research and Development offices,
facilitated by the UK Clinical Research Network (UKCRN) and
the Primary Care Research Network (PCRN). Written informed
consent was sought from all participants using an approved
consent form. Where participants chose to be interviewed by
telephone without forwarding a completed consent form, verbal
consent was recorded and transcribed verbatim and this fact was
recorded in accordance with the protocol approved by the Ethics
Committee. All data were anonymised to protect the confidenti-
ality both of organisations and individual participants.
Settings
GP practices in South East of England were selected for site
visits. They were small in size with 1 to 5 GPs for a practice. The
participants of a group discussion were from the Allergy and
Respiratory Expert Resource Group of the Royal College of
General Practitioners who were from a variety of GP practice
settings. Secondary care clinicians interviewed were from large
academic hospitals in the UK.
Sampling and recruitment
We purposively selected stakeholder roles that represented
multiple scenarios of adverse drug reaction recording and use. We
initially approached interviewees with an interest or expertise in
drug allergy and/or adverse drug reactions through personal
networks. We then snowballed [16] from this initial sample on the
basis of suggestions made by interviewees. Potential interviewees
were sent an email invitation that included information about the
research and a consent form. A single email reminder was sent to
those who did not respond to the initial invitation after three
weeks. Primary and secondary care clinicians, nurses and
pharmacists, clinical pharmacologists, informatics and industry
specialists, and managers working within the drug regulatory
sector took part in the interviews, group discussion and
observations. Among interviewees, there were four GPs, three
pharmacists, one nurse, three clinical pharmacologists, three
secondary care physicians (one anaesthetist, one junior hospital
physician and one paediatrician), two managers from the
medicines regulatory sector and one industry expert. The four
site visits were to GP practices with different clinical systems. They
were selected for the site visits, since the most developed UK
recording systems were those that found in primary care. We also
interviewed the secondary care clinicians as they could offer a
different context such as challenges of using less advanced
computer systems for recording adverse reactions. The variety of
stakeholders allowed us to gain an insight into frontline recording
practices in a range of settings, as well as underlying drivers.
Data generation and handling
Semi-structured interviews were the principal data source and
were employed to understand and obtain insights into perspectives
on and experiences of clinical documentation of adverse drug
reactions. Participants were asked about drug allergies and adverse
drug reactions separately while appreciating their relationship
mentioned above. Interviews were transcribed and checked by the
researcher for any errors, which were corrected. Interviews and
observations of relevant recording practices by GPs were made
during site visits and relevant screen images were captured. A
group discussion was held on approaches to accurate coding of
allergy with members of the Royal College of General Practition-
ers’ Allergy and Respiratory Expert Resource Group.
Data analysis
Data analysis was based on an appreciation of sociotechnical
principles [17] in evaluation of eHealth innovation. Data
collection and analysis took place concurrently, allowing us to
modify the topic guide for the future interviews and feeding back
emerging themes into subsequent data collection (e.g. by searching
for disconfirming evidence). Transcribed data from interviews, the
observations and field-notes from the discussion group were read
repeatedly by the researcher (BF, a clinician with an interest in
structured documentation), and emerging themes were identified
Table 1. Definitions.
Adverse drug reaction
An adverse drug is a response to a medicinal product, which is noxious and unintended. It is also known as a side effect. http://www.adrreports.eu/EN/glossary.html
Allergic drug reaction
Allergic drug reaction is an adverse drug reaction. It is an immunologically mediated reaction characterised by specificity, transferability by antibodies or lymphocytes,
and recurrence on re-exposure. Vervloet D, Durham S (1998) Adverse reactions to drugs. BMJ 316: 1511–1514
doi:10.1371/journal.pone.0093047.t001
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and coded for analysis. This was achieved by examining the
underlying tensions and emerging common themes within data
sources initially and then by comparing these across data sources
to produce a coherent account. Results were discussed with the
wider multi-disciplinary research team, allowing alternative
explanations for the findings and emerging themes to be explored
in detail. The main themes emerging were judged to be
converging towards saturation when no new themes emerged
across data collection activities.
Results
The final dataset comprised of 21 (i.e. four face-to-face and 17
telephone) interviews, observations made in four site visits, and
notes made during an expert discussion group involving 15
clinicians. Five key themes emerged from analysis of our data,
namely the: (1) diverse approaches to recording of drug allergies
(and more generally adverse drug reactions); (2) variable extent of
recording; (3) perceived benefits of recording; (4) perceived risks of
recording such information; and (5) the wider contextual
considerations including the training of professionals, incentives
and secondary uses of data.
Diverse approaches to recording of drug allergies
We found diverse approaches to recording drug allergy. All GPs
interviewed preferred to record this information in the electronic
record themselves rather than delegate this responsibility to other
members of the team, because they recognised the importance of
accurate documentation.
‘‘…I feel it is very important issue to record patient’s allergy and it has
to be 100% accurate therefore I thought that it is my role as a clinician
to enter all the allergy, and take sole responsibility for entering, and to
date nobody else enters allergy but me.’’ (Interview 11, GP/
observation)
In contrast, in hospitals, a wide range of professionals (e.g.
doctors, nurses and pharmacists) were involved in the recording of
the drug allergy and adverse drug reactions.
‘‘Absolutely the current situation is a combination of different healthcare
professionals. Basically nursing staff, medical staff, and pharmacy staff
can record allergies and adverse reactions on our system. Probably the
nursing record the highest percentage followed by pharmacists and then
by medical staff.’’ (Interviewee 2, Pharmacist, Secondary care)
In primary care, we observed that templates or pick lists of
terms were used to record drug allergy and adverse drug reactions.
We also observed that templates (where data entry fields were
bound to pre-assigned clinical codes) were commonly used for
structured recording. Participants reported that although tem-
plates allowed quick data entry and automatic coding, they
provided limited opportunity for recording contextual informa-
tion, which was typically captured within an accompanying free-
text narrative to aid interpretation of coded terms.
‘‘…I think sometimes it forces you to adapt your history to fit the boxes.
But at the same time in lots of ways I think it is better to have structure
because otherwise everyone will be putting very different things down and
some people may record information than others so that at least it gives a
sort of minimum level of information.’’ (Interviewee 11, GP)
The full dataset of an example GP template with attributes
constructed from various templates reviewed is shown in Table 2.
GPs were divided in their views on editing or removing
incorrect records in electronic systems. Some GPs said they
deleted incorrect drug allergy records to prevent false alerts, while
others argued against this practice.
‘‘I do remove because otherwise we get a warning every time which isn’t
necessary because it’s no longer valid.’’ (Interviewee 11, GP)
‘‘I do have a dilemma of removing it because at the time it was a valid
problem so I’m not removing an historic problem even though it’s not
valid now, but it was important at the time of… but there’s no other
way around that.’’ (Interviewee 4, GP)
We observed that severity of reaction could be documented in
some templates; this was however perceived to be clinically
unhelpful by several participants as grading of severity was often
subjective and not necessarily a reliable guide to the severity of
future reactions.
Although the primary reason for recording drug allergy and
adverse drug reactions was for direct patient care, in some
situations this information was also recorded with secondary uses
in mind – for example. pharmacovigilance by regulatory agencies
such as the UK Medicines and Healthcare Products Regulatory
Agency (MHRA). However participants reported that different
coding systems (i.e. Read codes, SNOMED-CT, DM&D and
MedDRA) were used by different organisations (i.e. primary,
Table 2. Data set of an example GP system template used for
drug allergy or drug intolerance.
Drug allergy/Drug intolerance
Clinician [Name]
Drug name [Name]
Read term for the
reaction/
[Read code]/
Read term for the
allergic reaction
[Read code]
Reaction type Adverse effect
Allergy
Intolerance
Date of recording [Date/Time]
Severity Minimal
Mild
Moderate
Severe
Very severe
Potentially fatal
Notes [Free-text
narrative]
Certainty Tentative
Unlikely
Possible
Likely
Certain
Absolute
doi:10.1371/journal.pone.0093047.t002
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secondary care and regulatory agencies). When data from multiple
databases were used in pharmacovigilance investigations, partic-
ipants stated that code mapping tables were needed to aggregate
data between multiple systems.
‘‘…SNOMED is for medical information and DM&D for product
information, two terminologies that are not used in medicines regulation.
There are approaches to develop a mapping where when we receive the
electronic file from the general practice that we identify the SNOMED
code and have it translated electronically into the MedDRA code and
that we identify the DM&D code and translate that into the
appropriate drug within our pharmacovigilance drug dictionary. We
need to do this to avoid manual resource being used re-coding thousands
of messages.’’ (Interviewee 15, Manager, MHRA)
Variable extent of recording
We found when a drug was discontinued because of drug allergy
or adverse drug reaction the reason for discontinuation was not
usually recorded in computer systems. The reason for discontin-
uation of a drug is important information that needs recording
because it provides the context of the reaction. Clinicians reported
difficulties in distinguishing between allergy, other adverse drug
reactions, intolerances and other side effects.
‘‘A lot of clinical staff struggles to make a difference between allergy
[and] adverse drug reactions.’’ (Interviewee 7, Pharmacist,
Secondary care)
Perhaps as a result of this, the participants felt the recording of
drug allergy and other adverse drug reactions was often
incomplete.
‘‘Well I think the biggest challenge is first of all whether it is recorded.’’
(Interviewee 8, Academic Pharmacologist)
This was at least in part attributed to the fact that recognition of
drug allergy and other adverse drug reactions was considered
difficult. None of the participants reported that they used scoring
tools [18] to help identify drug allergy or adverse drug reactions.
Taking a detailed history of the reported reaction was, however,
considered by participants to be very important and this was
therefore the recommended approach to clinical diagnosis. In
some hospital systems we observed, the presence of drug allergy
was not coded and this information could therefore only be
displayed back to the user as a free-text entry. As a result, this
information was not computable and not usable in CDSS for
decision support.
‘‘And if they have no known drug allergies then that’s the one entry
that’s codified. So basically when they go on to the allergy recording
screen, if they’ve no known drug allergies they can select that
automatically. But if they have an allergy or an adverse reaction then
they then they’ve got to type the information that associated with it.’’
(Interviewee 12, Pharmacist, Secondary Care)
We observed that in some GP systems, observed drug allergy
and adverse drug reactions could be recorded as a class effect (e.g.
penicillins or tetracyclines) while in other systems this could only
be recorded as individual drug reactions (e.g. phenoxymethylpe-
nicillin or oxytetracycine). Several GPs interviewed were often
unsure of the fact that the outputs from their prescribing CDSS
would be influenced by how information was recorded. That said,
the GPs felt the systems worked satisfactorily for them. Participants
reported that, in hospitals, specially trained coders read and
interpreted clinical notes for coding important concepts.
Perceived benefits of recording relevant information
We found a widespread appreciation of the need for the
accurate recording of drug allergy and adverse drug reactions.
This was particularly motivated by the potential safety gains from
computerised prescribing decision support.
‘‘I think the main issue is about documenting them in a coded way so
that if you were to prescribe that drug or a drug in the same class again
that you would actually get a warning. I think that is most important
things.’’ (Interviewee 4, GP)
One participant reported that some innovative decision support
tools had been piloted [19] – for instance, when drug allergy and
adverse drug reactions were suitably coded, intelligent pick lists for
prescribing drugs were possible as shown below.
‘‘So you know rather than…necessarily showing all the details it’s sort
of only as if were systems where permissive and straight took you away
from drugs where there may have been drug reactions or allergies in the
past and put them into the bottom of the [pick] list. So turned the
decision support on its head.’’ (Interviewee 3, Secondary Care
Physician)
Perceived risks of recording this information
We noted that although different healthcare professionals
recorded drug allergy and adverse drug reaction information in
electronic systems, not all followed the same diagnostic criteria,
which often resulted in inaccurate information.
‘‘Elsewhere I have worked with electronic prescribing; nursing staff have
also recorded information. And that led to particular problems when you
think about things like diarrhoea and so on with penicillin. That’s not
an allergy, clearly.’’ (Interviewee 2, Pharmacist, Secondary
care)
Perhaps, as a result of this and the practice of multiple recording
of this information, the participants reported the recording of
adverse drug reactions as often being inconsistent, inadequate and
incomplete.
‘‘I think it’s… actually the documentation is actually quite poor,
allergies and adverse reactions. And one reason for that is that there’s not
a single record…most patients’ have multiple records and the
information isn’t consistent across the records.’’ (Interviewee 6,
Anaesthetist, Secondary care)
We observed that a coded record of drug allergy or adverse
drug reaction was therefore not always an accurate record.
Participants suggested that a suspected drug allergy or suspected
adverse drug reaction was often recorded as a (implicitly definite)
drug allergy or adverse drug reaction, which resulted in an
inability to distinguish confirmed diagnosis (whenever this was
possible) from the majority of suspected reactions in the coded
record. Participants felt that ‘‘Drug allergy’’ was thus in some
Recording Drug Allergy and Adverse Drug Reactions
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respects a widely used and perhaps misused term as not all
recorded drug allergies were clearly established.
‘‘The trouble is that allergy you know is a very you know widely used
and misused word. You know a lot of people who have an adverse drug
reaction you know believe that it’s an allergy but of course it isn’t in true
terms, true immunological terms an allergy.’’ (Interviewee 8,
Academic Pharmacologist)
Participants stated that adverse drug reactions were often
incorrectly recorded as drug allergy with unintended consequences
for future prescribing; for example, prescribing of alternatives to
the antibiotic of choice when a suspected drug allergy to penicillin
was recorded.
‘‘The trouble is if the…there can be a downside to that in that if people
are recorded as having adverse reactions to drugs which they haven’t in
fact had an adverse drug reaction to then you know that can prevent a
potentially important treatment being given to patients. You know you
think of patients who are wrongly recorded as being allergic to penicillin
not then being given penicillin when it’s clearly the best treatment on a
future occasion.’’ (Interviewee 8, Academic Pharmacologist)
Wider contextual considerations: training, incentives and
secondary uses of data
Primary care-based participants reported that they did not have
formal training on how to record adverse drug reactions, whilst
participants working in some hospitals said that where relevant,
they were offered training.
‘‘As in most things with GPs we just try things don’t we, we just teach
ourselves quite often, no one taught me.’’ (Interviewee 11, GP)
‘‘Everybody that uses the system has a training programme and they are
shown what to do… junior doctors actually get feedback on their
performance based on alerts that fire off.’’ (Interviewee 2,
Pharmacist, Secondary care)
We noted that recording of adverse drug reactions in clinical
systems for direct patient care and for secondary use presented
different scenarios. In the first instance, future risk of a reaction
and, in the latter detailed contextual information of the reaction,
were recorded.
‘‘…you are trying to do very different use cases. In clinical care, you are
trying to run decision support…In pharmacovigilance you are trying to
collect to find adverse reactions not just allergies, most particularly in
medicines surveillance.’’ (Interviewee 12, Research Pharmacist)
Both scenarios reflected unscheduled (or spontaneous) recording
of information and there was no mandated scheduled (or routine)
recording of adverse drug reactions. Participants reported that
neither activity was incentivised in the UK.
Some participants felt that incentives for recording this
information were not a good idea. Patient safety and professional
standards should, the participants felt, to be the drivers for
recording or reporting adverse drug reactions.
‘‘No. I mean I think incentivising would not necessarily be you know
would be…I don’t think would be a good thing. I do actually think that
there should be some professional responsibility.’’ (Interviewee 8,
Academic Pharmacologist)
Discussion
Summary of main findings
There was widespread acceptance among healthcare profes-
sionals of the need for accurate recording of drug allergy and the
motivation for this was the potential safety gains achieved when
prescribing CDSSs are used. This helps to explain why drug
allergy alerts are less likely to be over-ridden than other forms of
prescribing alerts [22][23]. However, although recognised as
having different aetiologies, drug allergy and adverse drug
reactions were treated as synonyms in practice. The primary
reason being accurately diagnosing and distinguishing between
drug allergy and adverse drug reactions can be difficult outside
specialist facilities. These circumstances therefore lead to wide-
spread recording of suspected drug allergy and suspected adverse
drug reactions under the generic heading of ‘‘drug allergy’’ [19],
an approach that fails to enable optimal leverage of prescribing
CDSS [24].
This work has furthermore highlighted the importance of wider
contextual considerations, these including the ambiguity of clinical
diagnosis, the extent of the lack of diagnostic facilities, the role of
incentives and deficiencies of current recording systems. Our
findings showed that terms such as ‘drug allergy’ and ‘adverse drug
reactions’ are used in practice with disregard to their formal
definitions (Table 1). There is a tendency; it seems, for overuse of
the term ‘drug allergy’. Given the professional buy-in, the already
substantial recording, the opportunity to share structured data
throughout the NHS, and the major investments in prescribing
CDSS still taking place, this represents a ripe, clinically important
area for future research.
Strengths and limitations of this work
We purposively sampled those with an established interest in
this area, but also front-line clinicians and industry representatives;
hence we have been able to understand this issue from a broad
range of perspectives. These interview-based data were supple-
mented by observations made during site visits to GP practices,
data collected during a group discussion with the Allergy and
Respiratory Expert Resource Group of the Royal College of
General Practitioners and by reviewing relevant publications
[2,3,19–24], all of which helped us to contextualise and triangulate
findings. Interpretation of data was aided by discussions amongst
members of our multi-disciplinary group. The final few interviews
failed to generate any major new insights this indicating that
saturation had been achieved.
Data collection was carried out by the lead author (who is a
practising GP with a health informatics background) and whilst
this clearly facilitated the relevance of our work for existing clinical
practice, this influenced data generation and analysis. The multi-
disciplinary data analysis discussions however allowed for wider
reflection and input into data analysis. The site visits were confined
to one region in England and this may limit the transferability of
findings to other settings and clinical contexts. This issue needs to
be investigated through follow-on work. Detailed observation of
allergy documentation during site visits and analysis of allergy
records in GP systems for completeness and consistency were not
possible due to time and patient confidentiality related constraints.
They were limitations for triangulation of data collected during
analysis and should be addressed in future research.
Recording Drug Allergy and Adverse Drug Reactions
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Conclusions
It is important to accurately record the name of the suspected
drug, a description of observed reaction, future risk and any
contextual contributory factors when a patient is suspected of
having drug an adverse drug reaction in order to leverage the
benefits of prescribing CDSS. The information recorded and
coded in practice varies depending on the purpose of recording
and the nature of the tools available for recording. Although
healthcare professionals widely appreciate the importance of
recording this information there is at present no agreement
amongst clinicians on what needs to be recorded in EHRs and
how. The current approach to recording this information is thus
inconsistent between primary and secondary care, even though
this information increasingly needs to be sharable between care
providers in the context of care for individual patients and for
aggregation for monitoring purposes. As record sharing becomes
routine across the NHS, for example through shared medical
summaries, the aggregation of inconsistently captured drug allergy
data may introduce the risk of erroneous prescribing recommen-
dations.
A standard terminology used throughout clinical practice for
this documentation needs to be complemented by standardised
templates and user interface tools that encourage consistent and
high quality recording of information on drug allergies. Efforts
now need to be focused on improving professional standards in
diagnosis, documentation and reporting of drug allergies and
adverse drug reactions. This should be informed by further
research to develop comprehensive data sets and situation specific
terminology subsets. This will be crucially dependant on improved
capability for investigation of suspected drug allergy or an adverse
drug reaction. Our work strongly suggests that frontline clinicians
would welcome such developments, which are, it is believed, likely
to reduce risk of prescribing-related iatrogenic harm. This is an
area that it is important in particular for future iterations of drug
allergy guidelines to address [25].
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